HIV/AIDS Clinical Trials

Showing 1701-1720 of 1,802 trials

A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

NCT00303576

Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.

HIV Infections

International Partnership for Microbicides, Inc.112 participantsStarted Oct 2005

Kigali, Rwanda • Yeoville, Johannesburg, South Africa • Bloemfontein, South Africa +1 more locations

WITHDRAWNPhase 2

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

NCT00121017

The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir) plus tenofovir and emtricitabine.

HIV InfectionHepatitis C

Abbott200 participants

COMPLETEDPhase 2

Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding

NCT00158509

Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days. HIV infection can worsen genital herpes. In turn, it is possible that genital herpes increases the quantity of HIV secreted at the genital level in women infected by the 2 viruses. This study is dedicated to verify this hypothesis.

Herpes GenitalisHIV Infection

French National Agency for Research on AIDS and Viral Hepatitis215 participantsStarted Aug 2004

Bobo-Dioulasso, Burkina Faso

UNKNOWNPhase 4

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

NCT00122226

This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.

HIV InfectionsHIV-Associated Lipodystrophy Syndrome

Amsterdam UMC, location VUmc50 participantsStarted Jan 2003

Helsinki, Finland • Amsterdam, Netherlands • Amsterdam, Netherlands +10 more locations

A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

Related Searches

Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients

Two Approaches to Providing HIV/AIDS Services in the Community to People Living With HIV/AIDS

Impact of HIV on Measles and Measles Immunisation

An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots

Once Daily 3TC, Efavirenz and ddI for HIV Infection

Trial of SAVVY Vaginal Gel and HIV in Nigeria

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB

Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.